US2009317393A1PendingUtilityA1

Method of modifying glucose activity using polypeptides selectively expressed in fat tissue

55
Assignee: UNIV MARYLANDPriority: Feb 24, 2003Filed: Oct 25, 2007Published: Dec 24, 2009
Est. expiryFeb 24, 2023(expired)· nominal 20-yr term from priority
Inventors:Da-Wei GongJohn MclenithanAlan ShuldinerRongze Yang
A61P 3/08A61P 3/00A61K 38/1709C07K 14/575
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Isolated omentin polypeptides that selectively express in omental fat tissue and methods for the use of the polypeptides. The polypeptides can be used in a method for modifying insulin action and/or glucose metabolism in an animal. The polypeptides can be used to promote glucose uptake by animal adipocytes and other cells, tissues, and/or organs. The polypeptides can also used to provide a therapeutic treatment for diseases of or related to glucose metabolism and adipose tissues. The polypeptides are also incorporated into diagnostic tests and testing kits for diagnosing or detecting a disease or condition involving animal tissue that contains, uses, or expresses the polypeptide in an animal suspected of having the disease or condition.

Claims

exact text as granted — not AI-modified
1 . A method of decreasing glucose metabolism in an animal, comprising interfering with an activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3 in an animal in need of treatment, wherein upon interfering with an activity of said polypeptide, glucose metabolism in the animal is decreased. 
     
     
         2 . A method of decreasing insulin activity in an animal, comprising interfering with an activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3 in an animal in need of treatment, wherein upon interfering with an activity of said polypeptide, insulin activity in the animal is decreased. 
     
     
         3 . A method of treating obesity or type 2 diabetes in an animal, comprising interfering with an activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3 in an animal in need of treatment, wherein upon interfering with an activity of said polypeptide, obesity or type 2 diabetes in the animal is treated. 
     
     
         4 . The method of  claim 1 , wherein the interfering comprises administering a molecule that inhibits a signaling activity of the omentin polypeptide. 
     
     
         5 . The method of  claim 2 , wherein the interfering comprises administering a molecule that inhibits a signaling activity of the omentin polypeptide. 
     
     
         6 . The method of  claim 3 , wherein the interfering comprises administering a molecule that inhibits a signaling activity of the omentin polypeptide. 
     
     
         7 . The method of  claim 1 , wherein the interfering comprises administering a molecule that inhibits a metabolic activity of the omentin polypeptide. 
     
     
         8 . The method of  claim 2 , wherein the interfering comprises administering a molecule that inhibits a metabolic activity of the omentin polypeptide. 
     
     
         9 . The method of  claim 3 , wherein the interfering comprises administering a molecule that inhibits a metabolic activity of the omentin polypeptide. 
     
     
         10 . The method of  claim 4 , wherein the molecule inhibits binding of omentin to a receptor. 
     
     
         11 . The method of  claim 5 , wherein the molecule inhibits binding of omentin to a receptor. 
     
     
         12 . The method of  claim 6 , wherein the molecule inhibits binding of omentin to a receptor. 
     
     
         13 . The method of  claim 4 , wherein the molecule is an anti-omentin antibody. 
     
     
         14 . The method of  claim 5 , wherein the molecule is an anti-omentin antibody. 
     
     
         15 . The method of  claim 6 , wherein the molecule is an anti-omentin antibody. 
     
     
         16 . The method of  claim 7 , wherein the molecule is an anti-omentin antibody. 
     
     
         17 . The method of  claim 8 , wherein the molecule is an anti-omentin antibody. 
     
     
         18 . The method of  claim 9 , wherein the molecule is an anti-omentin antibody. 
     
     
         19 . The method of  claim 1 , wherein the activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3 is a signaling activity or a metabolic activity. 
     
     
         20 . The method of  claim 2 , wherein the activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3 is a signaling activity or a metabolic activity. 
     
     
         21 . The method of  claim 3 , wherein the activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3 is a signaling activity or a metabolic activity. 
     
     
         22 . A method of decreasing glucose metabolism in an animal, comprising administering to an animal in need of treatment a molecule that inhibits a signaling activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3, wherein upon inhibition of omentin polypeptide signaling activity, glucose metabolism in the animal is decreased. 
     
     
         23 . A method of decreasing glucose metabolism in an animal, comprising administering to an animal in need of treatment a molecule that inhibits a metabolic activity of the omentin polypeptide of SEQ ID NO:1 or the omentin polypeptide of SEQ ID NO:3, wherein upon inhibition of omentin polypeptide metabolic activity, glucose metabolism in the animal is decreased. 
     
     
         24 . The method of  claim 10 , wherein the molecule is an anti-omentin antibody. 
     
     
         25 . The method of  claim 11 , wherein the molecule is an anti-omentin antibody.

Join the waitlist — get patent alerts

Track US2009317393A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.